As a leading serum-free cell culture media provider in China, JSBiosciences boasts advanced technological advantages. It has gained extensive experience in supply and custom manufacturing of cell culture media products, as well as formulation development services. From 2011 to 2020, JSBiosciences had successively inaugurated the Lanzhou Phase I and Nantong Phase II serum-free dry powder media bases, as well as R&D centers in Shanghai and San Francisco, the US, to continue to reinforce its leading position in the industry.
The Lanzhou base (Phase I) of JSBiosciences comprises of P2, P3 biosafety laboratories and a cGMP-compliant dry powder media production workshop, which covers a total area of 3000 square meters. It adopts the world’s most advanced cell culture media production equipment and technologies, and is the first Chinese cell culture media manufacturer to introduce the perfusion technology. The laboratories are equipped with state-of-the-art instruments and equipment: cell clone screening instrument ClonePix2, online viable cell concentration analyzer, cell viability analyzer, bio-molecular interaction analyzer, etc. They have also introduced strict GLP management system and advanced project management system.
At the end of December 2019, JSBiosciences launched the "JS Bio - Phase II Serum-Free CCM Project" in Haimen, Nantong, which is aimed at the future demand for the production and supply of cell culture media in the biopharmaceutical industry at home and abroad. The project involves a total investment of several hundred million yuan, and covers a 28mu (5.2-ha) construction land. It applies advanced large-scale media production technology fully into the industrial production of cell culture media to ensure high-quality dry powder media production and the highest level of intellectual property protection for customers’ formulations. In the future, it is expected to become one of the most automated cell culture media production bases with the largest production capacity in the world.